Comparing Enhertu vs Kisqali
| Enhertu (fam-trastuzumab deruxtecan) | Kisqali (ribociclib) |
|
|---|
| Enhertu (fam-trastuzumab deruxtecan) | Kisqali (ribociclib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Breast Cancer, Solid Tumors, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||||||||||
| More about Enhertu (fam-trastuzumab deruxtecan) | More about Kisqali (ribociclib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Enhertu has an average rating of 8.0 out of 10 from a total of 29 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 3% reported a negative effect. |
Kisqali has an average rating of 8.6 out of 10 from a total of 31 ratings on Drugs.com. 84% of reviewers reported a positive effect, while 3% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Enhertu side effects |
View all Kisqali side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Enhertu prices |
View all Kisqali prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
136.8 hours |
54.7 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 174 drugs are known to interact with Enhertu:
|
A total of 736 drugs are known to interact with Kisqali:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
March 13, 2017 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.